BERGEN BRUNSWIG REVENUES CLIMB 20% TO $1.3 BIL. IN QUARTER; EARNINGS FLAT
Executive Summary
Bergen Brunswig revenues from continuing operations grew 20% to $1.3 bil. in the company's fiscal third quarter ended May 31. Through nine months, revenues were up 16% to $3.7 bil., the wholesaler said June 12. Earnings, however, were flat for the quarter at $17.2 mil. and down 11% to $38.1 mil. for the nine months. "Results for the third quarter were in line with the company's objectives despite lower price increases on pharmaceuticals and a lower overall gross profit margin rate than in prior year periods," CEO Robert Martini said. "We continue to meet the challenge of decreased forward buying opportunities and continuing lower margins through the reduction of general operating expenses and the ongoing consolidation into regional distribution centers." Bergen's margins on sales climbed from 9.3% to 9.4% for both the quarter and the nine months.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth